K.M.P. Biotech Co., Ltd. welcomed Prof.Dr. Ravee Teanpaisan, Advisor to the Medical and Innovation Research Institute, Research and Development Office, Prince of Songkla University, and Assoc. Prof. Dr. Worawit Vanichsuwan, M.D., Director of the Medical and Innovation Research Institute, Research and Development Office, Prince of Songkla University, as well as a lecturer and surgeon from the Department of Surgery, Faculty of Medicine, Prince of Songkla University.
The visit aimed to tour the probiotic manufacturing facility for human use, operating under Thai FDA standards, and to explore opportunities for expanding the market of Thai probiotic strains within the low-risk pharmaceutical category.
Â
Currently, two probiotic strains — Lactobacillus paracasei SD1 and Lactobacillus rhamnosus SD11 — have successfully passed evaluations for quality, safety, and efficacy through the Thai FDA monograph assessment process.
Â
The company is now awaiting low-risk pharmaceutical product registration approval, with plans to further expand marketing activities in both domestic and international markets.
